118 related articles for article (PubMed ID: 16309891)
1. Significance of serum CXCL10/IP-10 level in type 1 diabetes.
Shigihara T; Oikawa Y; Kanazawa Y; Okubo Y; Narumi S; Saruta T; Shimada A
J Autoimmun; 2006 Feb; 26(1):66-71. PubMed ID: 16309891
[TBL] [Abstract][Full Text] [Related]
2. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study.
Antonelli A; Fallahi P; Ferrari SM; Pupilli C; d'Annunzio G; Lorini R; Vanelli M; Ferrannini E
Diabet Med; 2008 Nov; 25(11):1349-53. PubMed ID: 19046227
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis.
Narumi S; Kaburaki T; Yoneyama H; Iwamura H; Kobayashi Y; Matsushima K
Eur J Immunol; 2002 Jun; 32(6):1784-91. PubMed ID: 12115662
[TBL] [Abstract][Full Text] [Related]
4. Diabetogenic T cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice.
Jaakkola I; Jalkanen S; Hänninen A
Eur J Immunol; 2003 Dec; 33(12):3255-64. PubMed ID: 14635033
[TBL] [Abstract][Full Text] [Related]
5. Expression of monocyte chemoattractant protein-1 in the pancreas of mice.
Li D; Zhu SW; Liu DJ; Liu GL; Shan ZY
Chin Med J (Engl); 2005 Aug; 118(15):1269-73. PubMed ID: 16117880
[TBL] [Abstract][Full Text] [Related]
6. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines.
Goldberg-Bittman L; Neumark E; Sagi-Assif O; Azenshtein E; Meshel T; Witz IP; Ben-Baruch A
Immunol Lett; 2004 Mar; 92(1-2):171-8. PubMed ID: 15081542
[TBL] [Abstract][Full Text] [Related]
7. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes.
Kawada K; Sonoshita M; Sakashita H; Takabayashi A; Yamaoka Y; Manabe T; Inaba K; Minato N; Oshima M; Taketo MM
Cancer Res; 2004 Jun; 64(11):4010-7. PubMed ID: 15173015
[TBL] [Abstract][Full Text] [Related]
8. Transient chemokine receptor blockade does not prevent, but may accelerate type 1 diabetes in prediabetic NOD mice.
Seifarth C; Mack M; Steinlicht S; Hahn EG; Lohmann T
Horm Metab Res; 2006 Mar; 38(3):167-71. PubMed ID: 16673207
[TBL] [Abstract][Full Text] [Related]
9. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.
Romagnani P; Maggi L; Mazzinghi B; Cosmi L; Lasagni L; Liotta F; Lazzeri E; Angeli R; Rotondi M; Filì L; Parronchi P; Serio M; Maggi E; Romagnani S; Annunziato F
J Allergy Clin Immunol; 2005 Dec; 116(6):1372-9. PubMed ID: 16337473
[TBL] [Abstract][Full Text] [Related]
10. Compartment-specific expression and function of the chemokine IP-10/CXCL10 in a model of renal endothelial microvascular injury.
Panzer U; Steinmetz OM; Reinking RR; Meyer TN; Fehr S; Schneider A; Zahner G; Wolf G; Helmchen U; Schaerli P; Stahl RA; Thaiss F
J Am Soc Nephrol; 2006 Feb; 17(2):454-64. PubMed ID: 16382019
[TBL] [Abstract][Full Text] [Related]
11. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
12. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells.
Heller EA; Liu E; Tager AM; Yuan Q; Lin AY; Ahluwalia N; Jones K; Koehn SL; Lok VM; Aikawa E; Moore KJ; Luster AD; Gerszten RE
Circulation; 2006 May; 113(19):2301-12. PubMed ID: 16682613
[TBL] [Abstract][Full Text] [Related]
13. IP-10 and type 1 diabetes: a question of time and location.
Christen U; Von Herrath MG
Autoimmunity; 2004 Aug; 37(5):273-82. PubMed ID: 15672495
[TBL] [Abstract][Full Text] [Related]
14. Identification of potent and selective RNA antagonists of the IFN-gamma-inducible CXCL10 chemokine.
Marro ML; Daniels DA; McNamee A; Andrew DP; Chapman TD; Jiang MS; Wu Z; Smith JL; Patel KK; Gearing KL
Biochemistry; 2005 Jun; 44(23):8449-60. PubMed ID: 15938634
[TBL] [Abstract][Full Text] [Related]
15. Early up-regulation of CXC-chemokine expression is associated with strong cellular immune responses to murine skin xenografts.
Lee EM; Park JO; Kim D; Kim JY; Oh KH; Park CG; Oh BH; Kim S; Ahn C
Xenotransplantation; 2006 Jul; 13(4):328-36. PubMed ID: 16768726
[TBL] [Abstract][Full Text] [Related]
16. Expression levels of CXC chemokine receptors 3 are associated with clinical phenotype of type 1 diabetes.
Yamada S; Oikawa Y; Sakai G; Atsumi Y; Maruyama T; Shimada A
Ann N Y Acad Sci; 2006 Oct; 1079():186-9. PubMed ID: 17130553
[TBL] [Abstract][Full Text] [Related]
17. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells.
Zipin-Roitman A; Meshel T; Sagi-Assif O; Shalmon B; Avivi C; Pfeffer RM; Witz IP; Ben-Baruch A
Cancer Res; 2007 Apr; 67(7):3396-405. PubMed ID: 17409450
[TBL] [Abstract][Full Text] [Related]
18. CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis.
Morimoto J; Yoneyama H; Shimada A; Shigihara T; Yamada S; Oikawa Y; Matsushima K; Saruta T; Narumi S
J Immunol; 2004 Dec; 173(11):7017-24. PubMed ID: 15557199
[TBL] [Abstract][Full Text] [Related]
19. Enterovirus markers and serum CXCL10 in children with type 1 diabetes.
Berg AK; Tuvemo T; Frisk G
J Med Virol; 2010 Sep; 82(9):1594-9. PubMed ID: 20648615
[TBL] [Abstract][Full Text] [Related]
20. IP-10 and type 1 diabetes: a question of time and location.
Christen U; von Herrath MG
Autoimmunity; 2004 Jun; 37(4):273-82. PubMed ID: 15518041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
